Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche J, Hermans C, Rolfo C, Peeters M, De Wever O, Lardon F, Siozopoulou V, Smits E, Pauwels P.

Oncoimmunology. 2018 Mar 19;7(7):e1440167. doi: 10.1080/2162402X.2018.1440167. eCollection 2018.

PMID:
29900042
2.

Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report.

Sorber L, Zwaenepoel K, Wouters A, Janssens A, Hiddinga B, Van Meerbeeck J, Lardon F, Pauwels P, Rolfo C.

J Clin Pathol. 2018 Aug;71(8):754-756. doi: 10.1136/jclinpath-2018-205210. Epub 2018 May 31. No abstract available.

PMID:
29853531
3.

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.

Keppens C, Tack V, Hart N', Tembuyser L, Ryska A, Pauwels P, Zwaenepoel K, Schuuring E, Cabillic F, Tornillo L, Warth A, Weichert W, Dequeker E; EQA assessors expert group.

Oncotarget. 2018 Apr 17;9(29):20524-20538. doi: 10.18632/oncotarget.24980. eCollection 2018 Apr 17.

4.

Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

De Waele J, Marcq E, Van Audenaerde JR, Van Loenhout J, Deben C, Zwaenepoel K, Van de Kelft E, Van der Planken D, Menovsky T, Van den Bergh JM, Willemen Y, Pauwels P, Berneman ZN, Lardon F, Peeters M, Wouters A, Smits EL.

Oncoimmunology. 2017 Dec 12;7(3):e1407899. doi: 10.1080/2162402X.2017.1407899. eCollection 2018.

PMID:
29399410
5.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P.

Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.

6.

Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Rottey S, Ferdinande L.

Pathology. 2017 Jun;49(4):397-404. doi: 10.1016/j.pathol.2017.02.002. Epub 2017 Apr 17.

PMID:
28427753
7.

CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.

Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, Hauben E, Rolfo C, Rottey S, Pauwels P.

Histopathology. 2017 Sep;71(3):357-365. doi: 10.1111/his.13230. Epub 2017 Jun 16.

PMID:
28383817
8.

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.

Weyn C, Van Raemdonck S, Dendooven R, Maes V, Zwaenepoel K, Lambin S, Pauwels P.

BMC Cancer. 2017 Feb 16;17(1):139. doi: 10.1186/s12885-017-3112-0.

9.

Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Marcq E, Siozopoulou V, De Waele J, van Audenaerde J, Zwaenepoel K, Santermans E, Hens N, Pauwels P, van Meerbeeck JP, Smits EL.

Oncoimmunology. 2016 Nov 28;6(1):e1261241. doi: 10.1080/2162402X.2016.1261241. eCollection 2017.

10.

A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.

Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P.

J Mol Diagn. 2017 Jan;19(1):162-168. doi: 10.1016/j.jmoldx.2016.09.009. Epub 2016 Nov 17.

PMID:
27865784
11.

CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Ferdinande L, Rottey S.

Pathobiology. 2016;83(6):327-33. doi: 10.1159/000446569. Epub 2016 Jul 8.

12.

Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, Van Meerbeeck J, Lardon F, Rolfo C, Pauwels P.

Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4. Review.

PMID:
27180141
13.

PP2A binds to the LIM domains of lipoma-preferred partner through its PR130/B″ subunit to regulate cell adhesion and migration.

Janssens V, Zwaenepoel K, Rossé C, Petit MM, Goris J, Parker PJ.

J Cell Sci. 2016 Apr 15;129(8):1605-18. doi: 10.1242/jcs.175778. Epub 2016 Mar 4.

14.

CD70: An emerging target in cancer immunotherapy.

Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P.

Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26. Review.

PMID:
26213107
15.

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.

Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J, Lardon F, Rolfo C, Deschoolmeester V, Pauwels P.

Oncotarget. 2015 Sep 8;6(26):22666-79.

16.

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.

Jacobs J, Zwaenepoel K, Rolfo C, Van den Bossche J, Deben C, Silence K, Hermans C, Smits E, Van Schil P, Lardon F, Deschoolmeester V, Pauwels P.

Oncotarget. 2015 May 30;6(15):13462-75.

17.

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.

Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P.

Transl Lung Cancer Res. 2014 Aug;3(4):250-61. doi: 10.3978/j.issn.2218-6751.2014.03.01. Review.

18.

Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study.

Zwaenepoel K, Merkle D, Cabillic F, Berg E, Belaud-Rotureau MA, Grazioli V, Herelle O, Hummel M, Le Calve M, Lenze D, Mende S, Pauwels P, Quilichini B, Repetti E.

Exp Mol Pathol. 2015 Feb;98(1):113-8. doi: 10.1016/j.yexmp.2015.01.005. Epub 2015 Jan 8.

19.

The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target?

Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C.

Curr Drug Targets. 2014;15(14):1284-92. Review.

PMID:
25511614
20.

Liquid biopsies in lung cancer: the new ambrosia of researchers.

Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Russo A, Pauwels P.

Biochim Biophys Acta. 2014 Dec;1846(2):539-46. doi: 10.1016/j.bbcan.2014.10.001. Epub 2014 Oct 16. Review. Erratum in: Biochim Biophys Acta. 2015 Jan; 1855(1):17. Santini, Daniele [added].

PMID:
25444714
21.

The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.

Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, Kerr K, Schuuring E, Thunnissen E, Dequeker EM.

PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.

22.

Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.

Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P, Vermorken JB, Peeters M, Van Camp G, Baay M, Lardon F.

Cancer Lett. 2014 Nov 28;354(2):365-77. doi: 10.1016/j.canlet.2014.08.039. Epub 2014 Sep 2.

PMID:
25192874
23.

Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.

Zwaenepoel K, Van Dongen A, Lambin S, Weyn C, Pauwels P.

Histopathology. 2014 Oct;65(4):539-48. doi: 10.1111/his.12414. Epub 2014 Aug 6.

PMID:
24621075
24.

Expression analysis on archival material revisited: isolation and quantification of RNA extracted from FFPE samples.

Deben C, Zwaenepoel K, Boeckx C, Wouters A, Pauwels P, Peeters M, Lardon F, Baay M, Deschoolmeester V.

Diagn Mol Pathol. 2013 Mar;22(1):59-64. doi: 10.1097/PDM.0b013e318269de3b.

PMID:
23370428
25.

Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta.

Louis JV, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S, Zwaenepoel K, Pijnenborg R, Landrieu I, Lippens G, Ledermann B, Götz J, Van Leuven F, Goris J, Janssens V.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6957-62. doi: 10.1073/pnas.1018777108. Epub 2011 Apr 11.

26.
27.

Specific regulation of protein phosphatase 2A PR72/B'' subunits by calpain.

Janssens V, Derua R, Zwaenepoel K, Waelkens E, Goris J.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):676-81. doi: 10.1016/j.bbrc.2009.06.096. Epub 2009 Jun 23.

PMID:
19555667
28.

Diversity in genomic organisation, developmental regulation and distribution of the murine PR72/B" subunits of protein phosphatase 2A.

Zwaenepoel K, Louis JV, Goris J, Janssens V.

BMC Genomics. 2008 Aug 20;9:393. doi: 10.1186/1471-2164-9-393.

29.

Spatial control of protein phosphatase 2A (de)methylation.

Longin S, Zwaenepoel K, Martens E, Louis JV, Rondelez E, Goris J, Janssens V.

Exp Cell Res. 2008 Jan 1;314(1):68-81. Epub 2007 Aug 7.

PMID:
17803990
30.

Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit.

Longin S, Zwaenepoel K, Louis JV, Dilworth S, Goris J, Janssens V.

J Biol Chem. 2007 Sep 14;282(37):26971-80. Epub 2007 Jul 16.

Supplemental Content

Loading ...
Support Center